PP
KNSA icon

Paloma Partners’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Paloma Partners’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-19,300
Closed -$482K – 703
2024
Q3 		$482K Buy
+19,300
New +$470K 0.01% 633

Other funds holding KNSA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Paloma Partners's KNSA Position: Q4 2024 in Review

Paloma Partners sold out of Kiniksa Pharmaceuticals (KNSA) in Q4 2024, closing a stake of 19,300 shares — an estimated $482K sold.

Paloma Partners first reported a position in KNSA in Q3 2024 and held it in 1 quarter. The position peaked at $482K in Q3 2024. 160 funds tracked by Wall St. Rank hold KNSA as of Q4 2024.

  • Paloma Partners reported no remaining Kiniksa Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Paloma Partners sold 19,300 Kiniksa Pharmaceuticals shares in Q4 2024, an estimated $482K.
  • Paloma Partners first reported a position in Kiniksa Pharmaceuticals in Q3 2024 and held it in 1 quarter.
  • Paloma Partners's Kiniksa Pharmaceuticals position peaked at $482K in Q3 2024.
  • 160 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q4 2024.

Based on Paloma Partners's 13F filing for Q4 2024, filed 14 Feb 2025.